BMS-986258 is a Monoclonal Antibody owned by Bristol-Myers Squibb, and is involved in 2 clinical trials, which are ongoing.

BMS-986258 (ONO-7807) inhibits T cell immunoglobulin mucin-3 (TIM-3) that regulates macrophage activation. Tim-3 mRNAs are over expressed in cancers cells. The drug candidate by blocking the TIM-3, promotes anti-tumor immunity and suppresses the tumor propagation.

The revenue for BMS-986258 is expected to reach a total of $56m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BMS-986258 NPV Report.

BMS-986258 is originated and owned by Bristol-Myers Squibb. Ono Pharmaceutical is the other company associated in development or marketing of BMS-986258.

BMS-986258 Overview

BMS-986258 (ONO-7807) is under development for the treatment of metastatic solid tumors including renal cell carcinoma (RCC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC). The drug candidate is administered by parenteral route. It is an immuno-oncology antibody which acts by targeting T cell immunoglobulin mucin-3 (TIM-3). It is developed based on protein therapeutics technology. It was also under development for the treatment of solid tumors in Japan.

Ono Pharmaceutical Overview

Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – BMS-986258

Report Segments
  • Innovator
Drug Name
  • BMS-986258
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.